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Abstract 
Nanoporous adsorbents are promising materials to augment the efficacy of haemodialysis 
for the treatment of end stage renal disease where mortality rates remain unacceptably 
high despite improvements in membrane technology. Complications are linked in part to 
inefficient removal of protein bound and high molecular weight uremic toxins including key 
marker molecules albumin bound indoxyl sulphate (IS) and p-cresyl sulphate (PCS) and large 
inflammatory cytokines such as IL-6. The following study describes the assessment of a 
nanoporous activated carbon monolith produced using a novel binder synthesis route for 
scale up as an in line device to augment haemodialysis through adsorption of these toxins. 
Small and large monoliths were synthesised using an optimised ratio of lignin binder to 
porous resin of 1 in 4.  Small monoliths showing combined significant IS, p-CS and IL-6 
adsorption were used to measure haemocompatibility in an ex vivo healthy donor blood 
perfusion model, assessing coagulation, platelet, granulocyte, t cell and complement 
activation, haemolysis, adsorption of electrolytes and plasma proteins. The small monoliths 
were tested in a niave rat model and showed stable blood gas values, blood pressure, blood 
biochemistry and the absence of coagulopathies. These monoliths were scaled up to a 
clinically relevant size and were able to maintain adsorption of protein bound uremic toxins 
IS, PCS and high molecular weight cytokines TNF−α and IL-6 over 60 minutes using a flow 
rate of 300 mL/min without platelet activation. The nanoporous monoliths where 
haemocompatible and retained adsorptive efficacy on scale up with negligible pressure drop 
across the system indicating potential for use as an in-line device to improve haemodialysis 
efficacy by adsorption of otherwise poorly removed uraemic toxins. 
Key words 
Nanoporous, activated carbon, uraemic toxins, haemodialysis, end stage renal disease 
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1. Introduction 
Nanoporous adsorbents offer a potential method by which to address the life-reducing 
complications associated with poor removal of protein bound and high molecular weight 
uraemic toxins during haemodialysis. Whilst more than two million patients with end stage 
renal disease (ESRD) are treated by haemodialysis worldwide mortality rates remain high. 
Almost half of all patients who receive a diagnosis of ESRD die within three years, most 
commonly as a result of cardiovascular co-morbidity followed by infection (1-4). 
Haemodialysis is a life sustaining therapy and an efficient method for removing excess fluid 
and highly water soluble small molecules such as ionic solutes and urea from blood. Urea is 
known to hydrolyse into cyanate and form carbamylated haemoglobin (5-8) and other 
carbamylated proteins and lipoproteins. However, there is debate as to whether urea is a 
“uraemic” toxin or whether its use as a marker of dialysis adequacy actually correlates with 
adequate removal of uraemic toxins with the most damaging effects on tissue physiology (9, 
10). Urea is rapidly cleared during standard haemodialysis whereas other uraemic retention 
solutes, particularly protein bound and high molecular weight molecules, are minimally 
cleared resulting in retention in ESRD patients (11). Indoxyl sulphate (IS) and p-cresyl 
sulphate (PCS) are protein bound uraemic toxins derived from protein metabolism (12). 
They have been shown, both within in vitro and in animal models, to cause endothelial 
damage and cardiovascular disease, and are associated with increased mortality in ESRD 
patients (12-17). To date a suitable method to remove these and the many other poorly 
removed protein bound and high molecular uraemic toxins (17) remains to be found (11, 
18).   
Addition of an adsorption device into the standard haemodialysis circuit has great potential 
to improve removal of such toxins (2, 19-23). Synthetic, activated carbon adsorbents offer 
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considerable advantages over other polymer based systems. They outperform other 
adsorbents through the existence of a highly developed internal surface area which is 
suitable for non-specific adsorption of predominantly hydrophobic, organic molecules. Early 
studies using various granular AC formulations from a range of natural sources showed 
some success but were ultimately constrained by variable performance, poor 
haemocompatibility particularly related to platelet loss, pressure drop and poor adsorption 
of larger biological molecules when coated (24-31). Advances in production technology 
using synthetic pre-cursors have improved activated carbon performance through carefully 
controlled formulation, carbonisation and activation procedures allowing the production of 
mechanically strong microbeads with an internal surface area of over 1500 m
2
g
-1
 (32-34). 
Additionally it is possible to significantly increase capacity for the removal of protein bound 
and high molecular weight uraemic toxins through the development of nanopores with 
diameter in the range of 10-100 nm (35-38). This structure can be maintained and potential 
for pressure drop reduced by the production of activated carbon monoliths, formed as 
extruded cylinders with numerous micro-diameter channels along which blood flows. We 
have previously shown that nanoporous activated carbon monoliths can adsorb protein 
bound uraemic and high molecular weight toxins which are poorly removed by 
haemodialysis alone (39). However, a monolith synthesis route which enabled the 
production of monoliths with attrition resistance and adsorptive capacity on scale up to a 
clinically relevant size was not possible using the previous synthesis route. The aim of the 
current study was to assess monoliths produced by a novel lignin binder route for 
haemocompatibility using ex vivo healthy donor and a niave rat haemoperfusion model. 
Maintenance of nanoporosity and adsorptive capacity on scale up was then assessed with 
the ultimate goal of providing a potential augmentation strategy for haemodialysis. 
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2. Materials and Methods 
2.1 Monolith synthesis 
Monoliths were synthesised using a novolac phenol-formaldehyde resin pre-cursor 
dissolved in a pore-forming solvent, ethylene glycol, together with a cross-linking agent, 
hexamethylenetetramine, and lignin binder. The ratio of lignin binder to nanoporous resin 
was optimised to a wt% ratio of 25:75. The pre-polymer solution was cured and the 
resulting resin cake was crushed, washed and dried to remove excess pore former then 
milled and formed into a dough for extrusion. The resulting monoliths were carbonised at 
700 °C and activated in carbon dioxide at temperatures of up to 880°C. Nanoporosity was 
controlled primarily by initial resin pore-former composition and the unique phase 
separation that occurs during the curing stage. Small monoliths were prepared with a 
diameter of 7 mm, length of 95 mm and contained 30 square micro-channels. Large 
monoliths were prepared with a diameter of 30 mm and length of 225 mm and contained 
600 square micro-channels with a diameter of 300 µm. The monoliths were encased in heat 
shrink polyolefin tubes supplied by RS Components Ltd (Northamptonshire, UK). The 
process sealed Leuer lock fittings to the ends of the monoliths prior to the perfusion studies 
(fig 1a and 1b). 
2.2 Physical characterisation of small and large monoliths 
The surface and internal porous morphology of the resultant monolithic materials were 
characterised by scanning electron microscopy (SEM) using a Sigma field emission gun  
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 Figure 1 (a) Small and large monoliths were produced using a novel lignin binder route with 
dimensions of 0.7 cm x 9.5 cm and 2.8 x 22.5 cm (diameter by length) and microchannel 
numbers of 30 channels and 600 channels respectively (b) The monoliths were encased in 
heat shrink polyolefin tubes  (c) In vitro plasma and whole blood experiments were 
conducted, perfusing fluid through the monolith microchannels at a flow rate of 5ml/min for 
the small monolith studies and 300 ml/min for the large monolith studies (d) A naive rat 
haemoperfusion model was used to carry out an in vivo safety assessment of the small 
monoliths 
 
(FEG)-SEM microscope (Carl Zeiss NTS, Cambridge, UK). The definition of pore size in 
nanoporous materials according to the International Union of Pure and Applied Chemistry 
(IUPAC) is that micropores are smaller than 2 nm in diameter, mesopores 2-50 nm and 
macropores larger than 50 nm.   The carbons used in this study were predominantly micro-
macroporous. Prior to measurement, the hierarchically porous monolithic materials were 
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dried under vacuum at 150°C overnight. The pore size distribution data was determined 
using a PoreMaster mercury intrusion porosimeter (Quantachrome Instruments Ltd, Hook, 
UK). Surface area was determined using an Autosorb-1 gas sorption analyser, 
(Quantachrome Instruments, USA) using Quantachrome data analysis software 
(Quantachrome ASiQwin) and the Brunauer, Emmett and Teller (BET) method.  
2.3 Adsorption of marker uraemic toxins by the small monoliths 
The small monoliths were primed with saline solution for 30 minutes at a flow rate of 5 
ml/min. A 20 ml volume of fresh frozen human plasma (Cambridge Bioscience) was spiked 
with IS (125 µM), PCS (250 µM) and IL6. The spiked plasma solution underwent continuous 
circulation through the monoliths and samples were collected over time. IS and PCS 
concentrations were measured by HPLC using a method described in (39) and IL6 
concentration was measured by ELISA according to manufacturer’s instructions using a 
plasma dilution of 1:5 (BD Biosciences). 
2.4Haemocompatibility testing of small monoliths 
Haemocompatibility studies were carried out according to ISO standard 10993-4:2002 (E) 
using freshly drawn healthy donor blood from an anonymised healthy donor database held 
by the NIHR Brighton & Sussex Clinical Research Facility using informed consent protocols 
(UK National Research Ethics System (NRES) Committee South East Coast – Brighton and 
Sussex REC reference 13/LO/1058). The small monoliths (7 mm x 95 mm with 30 micro-
channels) were pre-conditioned with saline (0.9% NaCl) for 30 minutes prior to continuous 
circulation of 20 ml of healthy donor blood through the monoliths for 60 minutes at a flow 
rate of 5 mL/minute (fig 1c). Plasma was prepared by centrifugation of blood samples at 
3500 rpm for 15 minutes. 
2.5 Complement activation 
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The presence of C3a, C4a and C5a was measured in plasma prepared from EDTA 
anticoagulated blood by enzyme linked immunosorbent assay (ELISA) (BD Biosciences). 
ELISAs were carried out according to manufacturer’s instructions issuing a 1 in 2000 dilution 
for C3a and C4a and a 1 in 40 dilution for C5a.  
2.6 Platelet activation 
The presence of PAC-1 and CD62 platelet activation markers (BD Biosciences UK) was 
measured in sodium citrate anticoagulated donor blood samples pre- and post- perfusion 
through monolith and tubing only controls using flow cytometry.  The first 2 mL blood was 
drawn and discarded. 2 mL of blood incubated with ADP (2 µM) (Sigma Aldrich, UK) for 5 
minutes was used as a positive control. Fresh whole blood samples (5µL) were incubated in 
the dark with PE/CD61 (10 µL), APC /D62P (10 µL) and FITC/PAC-1 (10 µL) antibody cocktail 
for 20 minutes, fixed using chilled 1% paraformaldehyde in PBS (1 mL) for 30 minutes at 4 °C 
and analysed using an Accuri C6 flow cytometer and BD CSampler software (version 
1.0.264.21). The flow cytometer was set to slow flow rate, with a forward scatter (FSC) 
threshold of 10’000 to collect 10’000 events on the platelet gate.  
2.7 Granulocyte activation 
Granulocyte activation was measured by testing lithium heparin anticoagulated donor blood 
samples for the presence of CD14/CD11b markers (Biolegend, UK) using flow cytometry. 
Positive control samples were prepared by incubating blood samples with interleukin 6 (IL-
6) (50 ng/mL) and interleukin 8 (IL-8) (50 ng/mL) for 60 minutes. Blood samples (100 µL) 
were incubated with PE/CD14 (20 µL) and APC/CD11b (20 µL) antibody cocktails for 20 
minutes.  Stained blood samples were incubated with lyse/fix buffer (1.5 mL) in the dark for 
30 minutes prior to centrifugation at 600g for 6 min, removal of supernatant and washing of 
cells in 2 mL stain buffer. Cells were pelleted and resuspended in 300 µL stain buffer for 
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analysis using flow cytometry. The flow cytometer was set to medium flow rate, with a 
forward scatter (FSC) threshold of 80’000 to collect 10’000 events.  
2.8 T cell activation 
T cell activation was assessed in EDTA anticoagulated blood samples by measuring the 
activation of STAT3 and STAT 5 intracellular phosphorylation pathways using flow 
cytometry. Whole blood samples (200 µL) were lysed, permeabilised and stained by 
incubating with PerCP/CD3, Alexa488/CD8, PE/CD4 antibody cocktail (20 µL) and 
Alexa647/STAT3 or STAT5 (20 µL) for 1 hour. Positive control samples were prepared using 
an IL-6 (50 ng/mL) and IL-8 (50 ng/mL) spike for STAT3 activation and interleukin 2 (IL-2) (50 
ng/ml) spike for STAT5 activation followed by incubation for 60 minutes. Cells were washed 
and resuspended in 200 µL stain buffer for analysis using flow cytometry with setting as for 
the granulocyte activation assay.  
2.9 Adsorption of uraemic toxins by the large monoliths 
Large monoliths (n=3) were pre-conditioned with intravenous infusion saline solution (0.9% 
NaCl, 0.15% KCl & 0.2% MgCl) (Baxter) for 30 minutes. A 400 mL volume of blood, anti-
coagulated with sodium heparin and commercially supplied by Cambridge Biosciences, was 
spiked with 1000 pg/mL IL-6 and tumor necrosis factor alpha (TNF-α), 125 µM IS and 250 
µM PCS and continuously perfused through the monolith or tubing controls for 60 minutes 
at a flow rate of 300 ml/min (LaboVAR 225 pump, Möller Medical GmbH Fulda Germany). 
Samples were collected after 0, 5, 30, 60 min. IS and PCS concentrations were measured by 
HPLC using a method described in (39) and IL6/TNF−α concentration was measured by 
ELISA according to manufacturer’s instructions using a dilution of 1:5 (BD Biosciences). 
Platelet activation was measured in the plasma derived from the timed blood samples as 
described in section 2.5. 
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2.11 In vivo safety assessment of small monoliths  
All studies were conducted under the governance of the UK Animals in Scientific Procedures 
Act (1986, amended 2012), with full local ethical approval. Animals were allowed free access 
to food and water prior to the study and housed under a 12 hour light/dark cycle at 20
o
C 
(+/-2
o
C).Adult male Sprague-Dawley rats (250-300 g, Charles River UK) were anaesthetised 
under isofluorane (induction at 5% in oxygen, maintenance at 1.5% in air for the duration of 
the study) and had catheters placed in the left carotid artery and right jugular vein. Mean 
arterial pressure was recorded at hourly intervals (Biopac US) and core body temperature 
recorded throughout the study. To maintain body temperature, the animals were 
maintained on regulated heat mats and covered with insulated materials as required. 
Blood samples were collected into lithium heparin coated tubes for blood gas analysis 
(Siemens Medical Diagnostics, UK) and plasma biochemistry prior to, and at hourly intervals 
throughout the study. After an initial 30 minute stabilisation period, the arterial catheter 
was connected to a carbon monolith (approximately 10cm by 1cm (length x diameter)) via a 
peristaltic pump (figure 1d). The blood was then returned to the animal via the catheter 
placed into the jugular vein. Flow rates throughout the 2-hour treatment period were set at 
2 ml/min with the total circuit volume not exceeding 10% of the circulating blood volume of 
the animal (ca. 3 ml maximum). The circuit was pre filled with heparinised saline solution 
(1000 U/L), with a saline bolus (ca. 2 ml) administered to the animal at the start of 
treatment to prevent hypotension. At the termination of the study, blood and tissue 
samples were collected under terminal anaesthesia. Blood samples for biochemistry were 
stored on ice before centrifugation (3500 rpm, 10 min, 4 
o
C) and storage at -80
o
C. Plasma 
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biochemistry (glucose, urea, albumin, total protein, ALT, AST, creatinine) was assessed using 
an automated COBAS system (Roche, UK) following manufacturer’s instructions.   
2.10 Statistical analysis 
Statistical analysis was carried out using GraphPad Prism 6.05 software and two-way ANOVA 
with Tukey’s multiple comparison tests. 
3. Results 
3.1 Physical characterisation of the large and small monoliths 
The synthesis and activation process resulted in a well-defined distribution of transport 
microchannels running in parallel along the length of the monoliths (fig 2a-c). The internal 
structure of the carbon monolith walls was visible in the SEMs as larger macroporous and 
smaller nanoporous domains. The mercury porosimetry pore size distribution plot indicated 
nanoporous domains in the 20-100 nm range in both the small and large monoliths with 
mean peak porosity of 55.6 nm and 62.1 nm respectively (fig 2d). The BET surface area was 
calculated by gas nitrogen porosimetry to be 1117 m
2
 g
-1
 in the small monoliths and 1056 
m
2
 g
-1
 in the large monoliths. 
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 Figure 2 (a) Scanning electron micrograph showing microchannel geometry and (b) 
nanoporous domains within the walls of the small and large monoliths (c) Mercury pore size 
distribution plots indicated consistent meso-macroporosity in the small and large monoliths 
with a mean pore size of 56 nm and 62 nm respectively and SBET surface area calculated by 
gas nitrogen porosimetry of 1117 and 1056 m
2
/g respectively  
 
3.2 Adsorption of marker uraemic toxins by the small monoliths 
The small monoliths synthesised using a 25% lignin binder were able to adsorb uraemic 
toxins IS and PCS, reducing them to neglible levels and reduced IL-6 concentration by 80% 
(fig 3). 
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 Figure 3 Adsorption of IS (125 µM), p-CS (250 µM) and IL-6 (1000 pg/ml) from spiked fresh 
frozen human plasma over time by the small monoliths synthesised using a 25:75 %wt ratio 
of lignin to nanoporous resin (n=3, mean+/-SEM) 
 
3.3 Haemocompatibility testing of the small monoliths 
3.3.1. Complement activation 
Blood perfused through the small monoliths over time did not cause significant complement 
activation when compared to the negative, tubing only control (p>0.05) (Fig 4a-c). Some 
complement activation was observed at baseline and a slight increase occurred in both the 
monolith and tubing only controls over the 60 minute perfusion cycle. However, this was 
significantly less than that of the zymosan A activated positive controls in which 
complement fragment concentrations increased from 1.5 ng/mL to 4.1 ng/mL for C3a (p< 
0.0001)(fig 4a), 1.6 ng/mL to 3.3 ng/mL for C4a (p<0.05) (fig 4b) and 3.9 pg/mL to 43.5 
pg/mL for C5a (p< 0.0001) (Fig. 4c). C5a concentration detected in the plasma was in the 
picogram range and significantly lower than that for C3a and C4a which was in the ng range.  
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Figure 4 Perfusion of freshly drawn healthy donor blood through the small monoliths over 
60 minutes stimulated no significant complement activation measured using (a) C3a (b) C4a 
and (c) C5a activation markers, no significant platelet activation measured using (d) PAC-1 
and (e) CD62P activation markers and no significant T cell activation, measured using 
phosphorylated (f) STAT3 and (g) STAT5 protein expression when compared to tubing only 
controls in comparison to the zymosan A, PMA and cytokine stimulated positive controls 
(mean+/-SEM, n=3), ** p < 0.01, **** p<0.0001 
 
3.3.2 Platelet activation 
A platelet sub-population was isolated from the total blood cell population using a R-
Phycoerythrin (PE) fluorophore conjugated CD61 antibody against the platelet surface 
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antigen glycoprotein IIIa. Within this platelet sub-population activated platelets were 
detected using a fluorescein isothiocyanate (FITC) fluorophore conjugated PAC-1 antibody 
and an allophycocyanin (APC) conjugated CD62p antibody (fig 4d-e). No significant platelet 
activation occurred following 60 minutes of perfusion through the small monoliths and the 
tubing only controls. No significant difference in the percentage of PAC-1 and CD62P 
positive platelets was observed when comparing the monolith and tubing only control 
following 60 mins continuous filtration through the ex vivo circuit.  In contrast, the PMA 
(200 nM) spike induced significant platelet activation (SEM±, n=3, p<0.0001). 
3.3.3 Granulocyte activation 
No significant difference in granulocyte activation was observed between the monolith and 
tubing only controls following 60 minutes perfusion, although granulocyte activation did 
occur in both circuits (data not shown). Granulocyte activation, measured by elevated 
CD11b expression, occurred over 30 and 60 minutes blood perfusion through both 
monoliths and control but was less than that measured in the cytokine stimulated positive 
control (SEM±, n=3). 8% granulocyte activation was measured at baseline, 20 ± 4% after 30 
minutes perfusion and 70 ± 13% after 60 minutes perfusion in both the small monolith and 
tubing only samples. 
3.3.4 T cell activation 
The PE conjugated CD3 antibody was used to identify the T cell subpopulation. Alexa 647 
conjugated STAT3 and STAT5 antibodies were used to identify the post-perfusion, activated 
T cells, IL6/IL8 (50 ng/mL) activated STAT 3 positive control and IL2 activated STAT 5 positive 
control (fig 4f,g). No up regulation of intracellular STAT phosphorylation pathways was 
detected following blood perfusion through the small monoliths over 60 minutes. Negligible 
levels of STAT3 phosphorylation and STAT5 phosphorylation and levels of 10-20% were 
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detected in the pre- and post-perfusion monolith samples, tubing only control samples and 
time 0 cytokine spiked positive controls. A significant increase in the cytokine stimulated 
positive control samples occurred over 60 minutes.  91 ± 3% STAT5 T-cell activation and 64 ± 
2% STAT3 T-cell activation was detected. No significant T cell activation, measured by 
phosphorylated STAT3 and STAT5 protein expression, was observed following blood 
perfusion through the monoliths over 60 minutes compared to the cytokine (50 ng/mL) 
stimulated controls (SEM ±, n = 3, p<0.0001). 
3.3.5 Blood biochemistry and coagulometry   
Haemoglobin and haematocrit values, blood cell count, ionic solutes, urea, creatinine, total 
protein, albumin, fibrinogen and coagulometry measures remained in normal range and 
were not removed significantly by blood perfusion through the small monoliths (Table 1). 
Limited reduction in platelet count, total protein and albumin concentration occurred 
following blood perfusion through the monoliths. Platelet count dropped from 261 ± 54 to 
230 ± 75 x109 cells/mL post- monolith perfusion. The total protein concentration dropped 
from 75.7 ± 2.5 g/L to 64 ±2 g/L and albumin concentration dropped from 46 ±1 to 39.7 ±0.6 
g/L, all remaining in normal concentration range.  A significant reduction in creatinine  
concentration occurred, reducing from 66.7 ± 13.6 to 17.7 ± 6 µmol/L. No change in 
activated partial thromboplastin times (aPPT) or International normalised ratio (INR) were 
observed. Fibrinogen concentration reduced from 2.8 g/L in the pre-perfusion blood 
samples to 2.1 g/L in the monolith post perfusion samples but remained within the normal 
reference range. 
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Table 1. Healthy donor blood perfused through the small monoliths at 5 ml/min for 90 mins 
did not produce significant changes in blood cell count (WBC, RBC, PLT), haematocrit (HCT) 
and haemoglobin (HB) measures of haemolysis, urea, creatinine, total protein and APPT and 
INR measures of coagulation compared to tubing only controls (mean+/-SD, n=3). 
 
 
Pre-perfusion Monolith Tubing Normal range 
HB (g/L) 140.8 ± 16.8 137.2 ± 30.4 132.8 ± 26.6 115 - 165 
WBC ×10
9
 cell/mL 7.4 ± 1.5 7.4 ± 2.1 7.9 ± 2.2 4.0 - 11.0 
PLT ×10
9
 cell/mL 261 ± 54 230 ± 75 288 ± 111 150 – 450 
RBC ×10
12
 cell/mL 4.76 ± 0.59 4.57 ± 1.09 4.40 ± 0.92 3080 – 5.80 
HCT (L/L) 0.416 ± 0.049 0.381 ± 0.095 0.365 ± 0.073 0.350 – 0.470 
Sodium (mmol/L) 139 ± 2 139.7 ± 0.6 137.0 ± 1.7 135-146 
Potassium 
(mmol/L) 
4.2 ± 0.2 4.1 ± 0.1 4.5 ± 0.2 3.2-5.1 
Urea (mmol/L) 4.8 ± 1.8 3.8 ± 1.4 4.8 ± 1.7 1.7-8.3 
Creatinine 
(µmol/L) 
66.7 ± 13.6 17.7 ± 5.0 69.0 ± 14.7 62-106 
Total protein (g/L) 75.7 ± 2.5 64 ± 2 74.7 ± 1.5 66-87 
Albumin (g/L) 46 ± 1 39.7 ± 0.6 45.3 ± 0.6 34-48 
 
Fibrinogen (g/L) 
2.8 ± 0.5 2.1 ± 0.4 2.8 ± 0.6 2.0 – 4.0 
APTT (S) 1.0 ± 0.1 1.0 ± 0.1 0.9 ± 0.1 0.8 – 1.2 
INR 0.1 1.1 ± 0.1 1.0 ± 0.0 0.8 – 1.2 
 
3.4 Adsorption of uraemic toxins by the large monoliths 
IS and PCS concentrations were reduced from 125 and 250 µM to negligible levels following 
perfusion through the large, 30 mm diameter monoliths for 90 minutes compared to the 
tubing only positive controls where IS and PCS concentration remained unchanged (figure 
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5a-d). The monoliths adsorbed IL-6 and TNF-α, significantly reducing IL-6 concentration 
from 711 to 162 pg/mL and TNF−α from 1070 to 441 pg/mL over a 90 minute perfusion 
cycle. A platelet activation study showed no significant activation of platelets over 90 
minutes of perfusion through the monoliths and controls (fig 6). A further study extending 
the perfusion cycle to 240 minutes showed continued reduction in IS, PCS and IL-6 (fig 7). 
3.5 In vivo safety assessment of small monoliths 
The in vivo monolith perfusion safety study indicated no major concerns with regard to 
biocompatibility. None of the studies conducted showed any evidence of coagulopathies, 
either in terms of excess bleeding or clotting abnormalities. The circuit was pre-filled with 
heparinised saline, thought there was no evidence that the monolith removed heparin form 
the circuit. Blood gas values remained stable throughout the duration of the study (Table 
XX), with only the bicarbonate level showing a moderate decline over the two-hour 
treatment period. This may be due to the amount of saline administered to the animal to 
replace blood volume. Plasma biochemistry values showed decreases in albumin and total  
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Monolith Tubing control
 Figure 5 Healthy donor blood spiked with IS (125 µM), p-CS (250 µM), IL-6 (1000 pg/ml) and 
TNF(1000 pg/ml) and perfused through the large monoliths at a flow rate of 300 ml/min. (a) 
IS (b) p-CS (c) IL-6 and (d) TNF−α concentration was significantly reduced following 90 
minutes continuous filtration compared to the tubing only control (SEM±, n=3), *p<0.05. 
 
 
Figure 6 Perfusion of healthy donor blood for 90 minutes through the large monoliths at 
haemodialysis flow rates did not stimulate platelet activation using (a) PAC-1 and (b) CD62P 
activation markers compared to tubing only controls. No significant difference in the 
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percentage of PAC-1 and CD62P positive platelets was observed when comparing the 
monolith and tubing only control. In contrast, the PMA (200 nM) spike induced significant 
platelet activation (SEM±, n=3), *** p<0.001. 
 
 
Figure 7 (a) Indoxyl sulphate, p-cresyl sulphate (125 µM IS, 250 µM p-CS spike) and (b) IL-6 (1 ng/ml 
spike) remaining following 240 minutes spiked blood perfusion through the large monoliths (mean 
+/-SEM, n=8) 
protein levels, which may have been due to adsorbance by the column, but are also as a 
result of the haemodilution caused by connection to the saline filled circuit and additional 
crystalloid boluses. Creatinine values rose at the end of the study, which may indicate a 
small degree of haemolysis within the circuit resulting from the continued action of the 
peristaltic pump. Although this difference in creatinine is significant, the values are not 
excessively high (Table 2). Mean arterial blood pressure remained stable throughout the 
duration of the study, indicating that the animals tolerated the procedure well. 
Table 2 Naïve rat haemoperfusion data showing the results from blood gas analyses, plasma 
biochemistry and direct measurement of the mean arterial pressure. Data were analysed using one 
way ANOVA. * p<0.05, ** p<0.01, ***p<0.001 vs pre-circuit (time 0) values. Data are shown as mean 
± SD, n=9 in each case. Abbreviations, alanine aminotransferase (ALT), aspartate aminotransferase 
(AST) 
  Pre-Circuit 60 mins 120 mins 
Blood Gas  
pH 7.4 ± 0.03 7.4 ± 0.04 7.4 ± 0.07 
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Hematocrit 43.3 ± 0.6 38 ± 2 37.7 ± 3.5 
HB (g/dl) 14.7 ± 0.2 13 ± 0.7 12.8 ± 1.1 
O2 Saturation 
(%) 
96 ± 1.3 96.4 ± 1.3 96.7 ± 0.9 
Sodium (mM) 135.4 ± 1.7 135.4 ± 1.6 134.2 ± 1.9 
Potassium (mM) 4.3 ± 0.2 4.5 ± 0.3 4.6 ± 0.7 
Calcium (mM) 1.3 ± 0.04 1.3 ± 0.05 1.3 ± 0.03 
Chlorine (mM) 101.5 ± 1.7 104.7 ± 2.1 104.1 ± 1.8 
Glucose (mM) 14.7 ± 3.2 14.2 ± 4 16.8 ± 7.2 
Bicarbonate 
(mM) 
26.7 ± 1.1 24.9 ± 2.6 22.8 ± 3.5* 
Plasma Biochemistry 
Albumin (g/L) 34.4 ± 2.8 26.9 ± 5.4** 25.8 ± 4.1*** 
Total Protein 
(g/L) 
49.1 ± 1.8 39.5 ± 7.4** 37.3 ± 4.9*** 
ALT (U/L) 48.9 ± 11.4 36.8 ± 10.4 42.6 ± 12.7 
AST (U/L) 67.9 ± 7.4 57.6 ± 15.9 103 ± 81 
Creatinine (µM) 20.6 ± 4.5 31.1 ± 8.4 35.6 ± 11.9** 
Physiological  
Mean Arterial 
Pressure 
(mmHg) 
98.7 ± 10.6 80.9 ± 17 82.2 ± 28.1 
 
4. Discussion 
The study provides evidence to support the haemocompatibility and efficacy of a scaleable 
nanoporous activated carbon monolith device for potential use to augment current 
haemodialysis therapy.  A range of haemocompatibility tests using healthy donor blood 
samples and a small animal blood perfusion modelling study demonstrated that the 
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monoliths are safe for use in direct blood contact. A novel lignin binder synthesis route was 
used to successfully scale up the device to a clinically feasible size without reducing 
adsorptive efficacy for marker protein bound and high molecular weight uraemic toxins. 
Whilst no previous studies on nanoporous activated carbon monoliths with the porous 
range demonstrated in this study have been described, in vitro study data exists for carbons 
in bead form include carbide derived carbons, phenolic resin derived activated carbons and 
carbon incorporated into a mixed matrix hallow fibre membrane form(40-42). The beads 
showed some efficacy in spiked plasma studies but offer no solution to the challenges of 
direct blood contact and pressure drop. Mixed membrane carbon incorporation offers an 
interesting alternative but may limit contact area for sufficient adsorption of high molecular 
weight molecules. In mixed membrane form significant IS and PCS removal was reported but 
no data was reported for high molecular weight species potentially because the membrane 
cut off limits direct contact. Previous studies comparing synthetic resin derived carbon bead 
activation burn off and adsorptive efficacy reported reduction of high molecular weight 
cytokine TNF matching that shown previously for CDCs but data is limited to batch 
adsorption studies from plasma. Within the current study a phenolic resin derived activated 
carbon monolith rather than bead based device was shown to reduce IS and PCS levels in 
spiked whole blood to negligible levels and IL6 and TNF levels by 80% and 60% respectively 
indicating a scaleable efficacy compared to bead based alternatives. The monolith design 
solves issues of haemocompatibility and pressure drop across the adsorbent device without 
resorting to coating with potential subsequent reduction in the molecular weight cut-off and 
adsorptive profile. 
There are many advantages in adapting the activated carbon form to a monolithic structure 
for direct blood perfusion but also many challenges in maintaining porous profile and 
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adsorptive efficacy.  Previous tests using a small monolith prototype and haemodialysis 
patient blood samples indicated that adsorption of protein bound and middle molecules 
was dependent on creating nanopores in the 2-100 nm range since adsorption of these 
solutes in carbon monoliths with narrow nanopores of <2 nm was limited (39). The 
challenge in scaling up the monolith was to maintain nanoporosity but also to design the 
monolith channel parameters to balance maximum adsorption with appropriate internal 
fluid dynamics (43). This was achieved in the current device iteration by using a constant 0.3 
mm microchannel channel size.  A short diffusion distance was provided for access to the 
internal porous surface area in the walls of the monolith and a micro-channel structure 
capable of minimising shear stress, maintaining laminar flow and thus reducing red blood 
cell fragility, haemolysis, platelet activation and thrombus formation. Previous studies with 
activated carbon granules containing narrow nanopores of < 2 nm have highlighted the 
tendency for excessive pressure drop, platelet consumption, albumin loss and potential for 
carbon fines release (30). The introduction of a monolithic design was therefore integral to 
minimise the tendency for flow irregularities, pressure drop and impact on blood cell 
fragility, platelet loss and protein adhesion.  
Binding of plasma proteins occurs as soon as blood contacts a foreign surface. Dominant 
plasma proteins albumin, fibrinogen and IgG coat a surface immediately but with a dynamic 
exchange with other plasma proteins over time (44). Protein surface coating in the 
extracorporeal circuit becomes problematic if proteins are denatured and expose activation 
sites for inflammatory pathway activation or in some cases if a negatively charged surface 
induces contact activation (44). Protein surface adhesion may also form a passivating layer, 
limiting any further inflammatory response. In the current study blood albumin and 
fibrinogen concentrations were reduced on contact with the monoliths However, total 
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protein, albumin and fibrinogen concentrations all remained within the normal reference 
range indicating a non-detrimental, dynamic, adsorptive equilibrium for these dominant 
plasma proteins over the initial time course of haemodialysis. Adsorption of dominant 
plasma protein serum albumin (66 kDa) and fibrinogen (340 kDa) did not prevent adsorption 
of  less concentrated high molecular weight IL-6 (28 kDa) and TNF−α (52 kDa), present in 
picogram quantities, and adsorbed predominantly within the nanoporous domains of the 
monoliths. The cause of this effect is not clear but could be related to the different 
hydrophobic domains within  the proteins. AC is a hydrophobic adsorbent and it has been 
reported that the TNF-α  trimer undergoes reversible dissociation into three monomeric 
units  in contact with hydrophobic surfaces  and therefore smaller molecules of IL-6 and 
TNF−α monomer (17 kDa) could be adsorbed predominantly within the nanoporous 
domains of the monoliths inaccessible to albumin (45). Results confirm no significant impact 
on total protein, electrolyte and haemolysis parameters using healthy donor blood perfused 
through the small monoliths over time. Albumin and platelet reduction was slight using the 
healthy blood samples in contrast to a previous study using post-haemodialysis blood 
samples where  a greater reduction in platelet count and albumin concentration was 
observed (39). A number of additional variables including differences in blood sample 
handling and monolith formulation may have influenced the heightened propensity for 
haemodialysis blood sample proteins and platelets to adhere but the results also support 
the premise that haemodialysis patient blood is primed for inflammation. 
The haemocompatibility tests were carried out on the small monolith prototypes according 
to ISO 10993 for blood contacting medical devices assessing platelet activation, granulocyte 
activation, activation of t-cell intracellular phosphorylation pathways for STAT3 and STAT5 
using flow cytometry, complement fragment concentration for C3a, C4a, C5a using ELISA 
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and coagulometry assays measuring pro-thrombin, APPT clotting times and fibrinogen 
concentration. The signal transducer and activator of transcription (STAT) family are a group 
of proteins activated by cytokines and growth factors through receptor associated kinase 
phosphorylation followed by dimerization, translocation into the nucleus and transcription 
of genes related to cell proliferation and the inflammatory response.  They were used in this 
study as the earliest indicator of T-cell activation on inflammatory stimulus by the 
monoliths. Some complement activation and in particular granulocyte activation was 
detected at the 60 minute time point for both monolith and tubing only negative controls. 
Complement activation is known to occur routinely on exposure to a foreign surface within 
haemodialysis, cardiopulmonary bypass and apheresis via the alternative pathway (46-48). 
The small, cationic peptides C3a, C4a and C5a are anaphylatoxins which are free in the 
plasma and bind to neutrophils and monocytes to promote ROS production, cytokine 
release and cell hyper-adhesion. Activation was no more than the tubing only controls and 
was markedly limited when compared to the zymozan A activated, positive control blood 
samples, indicating that the artificial surfaces within the perfusion model itself and not the 
monoliths promoted some activation of inflammatory pathways.  
The large monoliths maintained adsorptive efficacy for the uraemic toxins IS and PCS and 
cytokines IL-6 and TNF−α οn scale up and at  haemodialysis flow rates with minimal 
pressure drop. Further work is required to establish breakthrough parameters and the 
impact of rebound release on adsorption but the current study indicates that an adsorptive 
equilibrium is maintained over 4 hours perfusion time. The broad spectrum adsorptive 
capacity of the activated nanoporous carbon monoliths for organic molecules indicates that 
these monoliths will have great capacity to remove other poorly removed protein bound 
and middle molecule uraemic toxins from the growing family of uraemic toxins known to 
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remain after standard haemodialysis treatments and represented by these marker 
molecules.  
In summary, whilst haemodialysis patients have an immunosuppressive and altered 
haemostatic balance so that blood cell fragility and inflammatory response on contact with 
foreign surfaces will inevitably be hypersensitised toward inflammation (49) the results of 
the current study show that, using healthy donor blood, a nanoporous activated carbon 
monolith does not exacerbate blood cell activation according to ISO 10993 
haemocompatibility measures. Haemocompatibility was also demonstrated using an in vivo 
haemoperfusion safety model where no disruption of blood biochemistry or coagulopathy 
occurred. The scaled up device maintained the internal nanoporous structure necessary to 
augment haemodialysis efficacy through broad spectrum adsorption of small, protein bound 
and high molecular weight uraemic toxins.   
5. Conclusion 
A novel lignin binder synthesis route has been used to synthesise nanoporous activated 
carbon monoliths with maintained adsorptive capacity for marker protein bound and high 
molecular weight toxins on scale up and testing at haemodialysis flow rates. These toxins 
currently remain following haemodialysis and contribute to poor survival related to 
cardiovascular disease and infection. The carbon monolith is safe and shows good 
biocompatibility when tested in naive rats. Such a device could potentially be used as an in-line 
haemoperfusion device to sit in line with and augment the clearance of uraemic toxins 
poorly removed by standard haemodialysis.  
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